Gene expression markers and treatment of multiple sclerosis
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
1. A method of treating a mammalian subject suffering from multiple sclerosis (MS), comprising:
a) measuring, in a cerebrospinal fluid (CSF) sample of the subject, an expression level of tissue inhibitor of metalloproteinase 1 (TIMP1);
b) comparing the expression level measured in a) to a reference expression level of TIMP1 in a CSF sample of an MS-negative control;
c) identifying the subject as more likely to have an increased expression level of interleukin-17 (IL-17) as compared to an MS-negative control when the expression level measured in a) is above the reference expression level; and
d) administering an effective amount of an IL-17 antagonist to the subject identified in c),
wherein the IL-17 antagonist is an anti-IL-17 antibody or an anti-IL-17 receptor antibody.
2. The method of claim 1 , wherein the mammalian subject is a human.
3. The method of claim 1 , wherein the multiple sclerosis is characterized by an increased expression level of IL-17.
4. The method of claim 3 , wherein the expression level of IL-17 is elevated in the CSF of the subject.
5. The method of claim 1 , wherein the IL-17 having the increased expression level is IL-17AA.
6. The method of claim 1 , wherein the a) comprises measuring the expression level of the RNA transcript or the protein product of TIMP1.
7. The method of claim 1 , further comprising:
measuring, in a biological sample of the subject, an expression level of at least one gene selected from the group consisting of LRG1, CXCL1, CXCL5, CXCL10, IL-8, NFκBIZ, YKL40, and G-CSF;
comparing the measured expression level of the at least one gene to a reference expression level of the at least one gene of an MS-negative control; and
administering an effective amount of the IL-17 antagonist to the subject whose expression level of TIMP1 measured in a) and the measured expression level of the at least one gene are above the reference expression level of TIMP1 and the reference expression level of the at least one gene.
8. The method of claim 7 , wherein the at least one gene
i) comprises NFκBIZ;
ii) is selected from the group consisting of CXCL1, CXCL5, and CXCL10, or
ii) is selected from the group consisting of LRG1 and G-CSF.
9. The method of claim 1 , wherein the IL-17 antagonist is an anti-IL-17 antibody and the anti-IL-17 antibody binds to an IL-17A homodimer, IL-17F homodimer, and/or IL-17AF heterodimer.
10. The method of claim 1 , wherein the anti-IL-17 antibody or the anti-IL-17 receptor antibody is selected from the group consisting of brodalumab, secukinumab, ixekizumab, bimekizumab, CNTO 6785, ALX-0761, afasevikumab, and combinations thereof.
11. The method of claim 1 , further comprising administering to the subject at least one MS-treating agent selected from the group consisting of dimethyl fumarate, FTY-720, nataluzimab, corticosteroids, β-interferon, glatiramer acetate, teriflunomide, mitoxantrone, anti-CD20 antibody, and combinations thereof.
12. A method of treating a mammalian subject suffering from multiple sclerosis (MS), comprising: administering an interleukin-17 (IL-17) antagonist to a subject who has been identified as more likely to have an increased expression level of IL-17 as compared to an MS-negative control, wherein the identification comprises detecting, in a cerebrospinal fluid (CSF) sample of the subject, an increased expression level of tissue inhibitor of metalloproteinase 1 (TIMP1) relative to a reference expression level of TIMP1 in a CSF sample of an MS-negative control, and wherein the IL-17 antagonist is an anti-IL-17 antibody or an anti-IL-17 receptor antibody.
13. The method of claim 12 , wherein the mammalian subject is a human.
14. The method of claim 12 , wherein the multiple sclerosis is characterized by an increased expression level of IL-17.
15. The method of claim 12 , wherein the identification further comprises detecting, in a biological sample of the subject, an increased expression level of at least one gene selected from the group consisting of LRG1, CXCL1, CXCL5, CXCL10, IL-8, NFκBIZ, YKL40, and G-CSF relative to a reference expression level of the at least one gene of an MS-negative control.
16. The method of claim 15 , wherein the biological sample is a biological fluid selected from the group consisting of CSF, serum, plasma, and combinations thereof.
17. The method of claim 12 , wherein the anti-IL-17 antibody or the anti-IL-17 receptor antibody is selected from the group consisting of brodalumab, secukinumab, ixekizumab, bimekizumab, CNTO 6785, ALX-0761, afasevikumab, and combinations thereof.
18. The method of claim 12 , further comprising administering to the subject at least one MS-treating agent selected from the group consisting of dimethyl fumarate, FTY-720, nataluzimab, corticosteroids, β-interferon, glatiramer acetate, teriflunomide, mitoxantrone, anti-CD20 antibody, and combinations thereof.